Daiichi Sankyo Company Research Report

Company Overview

• Name: Daiichi Sankyo, Inc.

• Mission: The company aims to enrich the quality of life around the world through the development of innovative pharmaceuticals.

• Founded: Established in 2006 by the merger of two 100-year-old Japanese pharmaceutical companies.

• Key People: Hiroyuki Okuzawa recently appointed as Chief Executive Officer as of January 30, 2025.

• Headquarters: U.S. headquarters is located at 211 Mt. Airy Road, Basking Ridge, NJ, 07920-2311.

• Number of Employees: Approximately 16,000 globally, with 1,800 based in the U.S.

• Revenue: No information is available.

• Known For: Daiichi Sankyo is recognized for its innovative medicines, especially in the fields of oncology and cardiovascular diseases.

Products

1. DATROWAY® (Datopotamab Deruxtecan-dlnk)

• Description: Approved for previously treated metastatic HR Positive, HER2 Negative Breast Cancer.

• Key Features:

• Part of adjuvant regimen for patients with early-stage non-small cell lung cancer at high risk of relapse.

2. ENHERTU® (Fam-trastuzumab Deruxtecan-nxki)

• Description: Approved in the U.S. as the first HER2-directed therapy for patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer following disease progression after one or more endocrine therapies.

• Key Features:

• Breakthrough therapy with specific HER2 targeting.

3. INJECTAFER® (Ferric Carboxymaltose Injection)

• Description: Used for iron deficiency anemia.

• Key Features:

• Known for its efficiency in improving hemoglobin levels.

4. SAVAYSA® (Edoxaban) Tablets

• Description: Used for thrombosis and stroke risk reduction.

• Key Features:

• Effective as an anticoagulant with a safe profile.

5. TURALIO® (Pexidartinib)

• Description: Treats tenosynovial giant cell tumor.

• Key Features:

• Present with liver toxicity warning.

6. VANFLYTA® (Quizartinib)

• Description: Targeted therapy for specific gene mutations in acute myeloid leukemia.

• Key Features:

• Effective in FLT3-ITD negative AML.

Recent Developments

• New Leadership:

• Hiroyuki Okuzawa appointed as Chief Executive Officer as of January 2025.

• New Product Approvals:

• DATROWAY® approved in the U.S. for patients with previously treated metastatic HR Positive, HER2 Negative Breast Cancer.

• ENHERTU® approved for HER2 Low or HER2 Ultralow Metastatic Breast Cancer.

• Research and Development:

• Initiated TROPION-Lung12 Phase 3 trial evaluating DATROWAY®.

• Establishment of a "Smart" research laboratory in San Diego to expedite drug discovery.

• Partnerships and Collaborations:

• Acquired intellectual property rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH.

• Strategic collaboration with Sarah Cannon Research Institute to accelerate new cancer medicines development.

Note:

For additional information on corporate governance, global structure, and other operational details, visit the [global website](https://www.daiichisankyo.com/).

Disclaimer: The information contained in this report is based on the data provided and may be subject to changes or updates not reflected in this document. Please refer to the company's official communications and releases for the most current information.